| GEN |
Genmab, de Deense parel
Ofatumumab Demonstrates Superiority Versus Teriflunomide in Two Head-to-Head Phase III Multiple Sclerosis StudiesCompany AnnouncementIn ASCLEPIOS I and II, ofatumumab (OMB157) met primary endpoi...
|
Traveler01 |
| GEN |
Genmab, de Deense parel
Genmab Signs Agreement with Janssen for Next-Generation CD38 Antibody, HexaBody-CD38Company AnnouncementGenmab signs agreement with Janssen Biotech, Inc. to collaborate exclusively on next...
|
Traveler01 |
| GEN |
Genmab, de Deense parel
July 12, 2018 5:57 AM UTCGenmab Enters Strategic Partnership with Immatics to Discover and Develop Next Generation Bispecific Cancer ImmunotherapiesCompany AnnouncementGenmab gains exclusive a...
|
Traveler01 |
| GEN |
Genmab, de Deense parel
November 8, 2017; Copenhagen, Denmark;Interim Report for the First Nine Months Ended September 30, 2017HighlightsUSD 871 million in net sales of DARZALEX (daratumumab); resulting in ...
|
Traveler01 |
| GEN |
Genmab, de Deense parel
Company AnnouncementNet sales of DARZALEX in the second quarter of 2017 totaled USD 299 millionGenmab will receive royalties on worldwide net sales from Janssen Biotech, Inc.Copenhagen, Denmar...
|
Traveler01 |
| GEN |
Genmab, de Deense parel
May 10, 2017; Copenhagen, Denmark; Interim Report for the First Quarter of 2017HighlightsUSD 255 million in net sales of DARZALEX (daratumumab); resulting in royalty income of DKK 211 ...
|
Traveler01 |
| GEN |
Genmab, de Deense parel
Company AnnouncementCopenhagen, Denmark; February 22, 2017 — Genmab A/S (Nasdaq Copenhagen: GEN) announced today its Annual Report for 2016. Below is a summary of business progress and financial ...
|
Traveler01 |
| GEN |
Genmab, de Deense parel
Een nieuwe aanpassing van de op 22 februari te publiceren cijfers.Company AnnouncementCopenhagen, Denmark; February 6, 2017 — Genmab A/S (Nasdaq Copenhagen: GEN) announced today that it has ...
|
Traveler01 |
| GEN |
Genmab, de Deense parel
ir.genmab.com/releasedetail.cfm?Relea...derde kwartaal Genmab...
|
Traveler01 |
| GEN |
Genmab, de Deense parel
ir.genmab.com/releasedetail.cfm?Relea...Daratumumab Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration in Combination with Standard of Care Regimens fo...
|
Traveler01 |
| GEN |
Genmab, de Deense parel
The trial is the latest in a string of successful studies of Darzalex, which JJ is co-developing with Danish biotech group Genmab, prompting Jefferies analyst Peter Welford to estimate that the d...
|
Traveler01 |
| GEN |
Genmab, de Deense parel
2,5 miljoen stuks in de eindveiling. Iemand een idee?...
|
Traveler01 |